Advertisement
Product › Details
ABI-009 (Aadi Bioscience / Celgene)
Next higher product group | cancer drug_o | |
Status | 2017-05-08 development p2 existent | |
Organisation | Aadi Bioscience Inc. | |
Organisation 2 | Celgene Corporation (Nasdaq: CELG) | |
Group | Bristol Myers Squibb (BMS) (Group) | |
Aadi Bioscience, Inc.. (5/8/17). "Press Release: Aadi Bioscience Closes $23 Million in Series A Funding". Pacific Palisades, CA.
Lead Registration study in Advanced PEComa on Target for 2018 Completion of Enrollment
Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced the completion of a $23 Million Series A round. The financing was led by Hermed Capital with participation from Celgene Corporation, Vivo Capital, Decheng Capital, the Helsinn Investment Fund and Star Summit Ventures. The company will use the capital to drive the clinical programs for ABI-009, its targeted albumin-bound mTOR inhibitor.
“We are extremely pleased with the participation and interest of our investors and now stand poised to develop the potential of what we believe is a best-in-class mTOR inhibitor,” said Neil Desai, Ph.D., Founder and CEO of Aadi.
Aadi is currently enrolling its registration trial for advanced Perivascular Epithelioid Cell tumors (PEComa), an extremely rare form of sarcoma. Aadi received agreement from the FDA on the design of its phase 2 registration study for the treatment of advanced PEComa with ABI-009. The study will enroll approximately 30-35 patients and the primary endpoint for the study is the overall response rate. Earlier this month, an independent data monitoring committee (DMC) reviewed the available data and concluded that the study should continue without modification.
Aadi’s other planned clinical programs include pulmonary hypertension (phase 1), early stage bladder cancer (phase 2) and pediatric cancers (phase 1). It continues to investigate applications of ABI-009 in cancer indications as well as cardiovascular and other diseases.
Dr. Desai is also pleased to welcome new directors to the board of Aadi including Carlo Montagner (Specialised Therapeutics), Richard Maroun (Frazier Healthcare Partners), Jerry Xiao (Hermed Capital) and Mahendra Shah (Vivo Capital).
About Aadi and ABI-009
Aadi is a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of ABRAXANE®, ABI-009 and the nab® technology platform. Aadi’s lead product is ABI-009, a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin. Aadi aims to develop the full potential of the albumin-bound mTOR inhibitor in diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of effective drug delivery, safety or effective targeting to the disease site. In a phase 1 study ABI-009 was well tolerated at intravenous doses significantly higher than other mTOR inhibitors and its pharmacokinetic profile, with high Cmax and AUC, is very different from the approved mTOR inhibitors. In animal models, ABI-009 has greater antitumor efficacy than the oral mTOR inhibitors at the same dose. Similar to ABRAXANE®, albumin-bound rapamycin is expected to have high tumor penetration due to mechanisms of albumin uptake in tumors and other areas with tissue remodeling or inflammation. ABI-009 was licensed to Aadi in 2014 by Celgene Corporation (NASDAQ:CELG).
ABRAXANE® and nab® are registered trademarks of Celgene Corporation.
Contacts
Aadi Contact:
Email: info@aadibio.com
website: www.aadibio.com
or
PR: Paola Bonvicini
PH: +41 91-985-21-21
info-hhc@helsinn.com
Record changed: 2023-07-10 |
Advertisement
More documents for cancer drug_o
- [1] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
- [2] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [3] Medigene AG. (11/21/23). "Press Release: Medigene AG Announces Prioritization of Pipeline and Resource Allocation as Well as Extension of Cash Runway". Planegg....
- [4] Nanobiotix S.A.. (7/10/23). "Press Release: Nanobiotix Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3". Paris & Cambridge, MA....
- [5] Bicycle Therapeutics plc. (6/23/23). "Press Release: Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer". Cambridge & Boston, MA....
- [6] Boundless Bio, Inc.. (5/16/23). "Press Release: Boundless Bio Announces $100 Million Oversubscribed Series C Financing Co-led by Leaps by Bayer and RA Capital Management". San Diego, CA....
- [7] Oniria Therapeutics, S.L.. (5/11/23). "Press Release: Oniria Therapeutics Closes €1.28 Million Seed Funding Round". Barcelona....
- [8] Pieris Pharmaceuticals, Inc.. (4/17/23). "Press Release: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting". Boston, MA....
- [9] Molecure S.A.. (3/30/23). "Press Release: Molecure Announces Full Year Financial 2022 Results – a Year of Significant Progress". Warsaw....
- [10] Bicycle Therapeutics plc. (1/4/23). "Press Release: Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer". Cambridge & Bos...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top